Equities
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.001
  • Today's Change0.00 / 0.00%
  • Shares traded18.17m
  • 1 Year change-99.97%
  • Beta2.4291
Data delayed at least 20 minutes, as of Aug 28 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Melodiol Global Health Ltd had net income fall 59.98% from a loss of 32.78m to a larger loss of 52.45m despite revenues that grew 210.13% from 6.32m to 19.60m over the same period.
Gross margin15.38%
Net profit margin-181.22%
Operating margin-136.63%
Return on assets-124.57%
Return on equity-389.56%
Return on investment-387.77%
More ▼

Cash flow in AUDView more

In 2023, cash reserves at Melodiol Global Health Ltd fell by 696.00k. Cash Flow from Financing totalled 7.51m or 38.29% of revenues. In addition the company used 8.14m for operations while cash used for investing totalled 81.00k.
Cash flow per share-8.29
Price/Cash flow per share--
Book value per share-0.5149
Tangible book value per share-0.9711
More ▼

Balance sheet in AUDView more

Melodiol Global Health Ltd has a Debt to Total Capital ratio of 172.62%.
Current ratio0.2398
Quick ratio0.1594
Total debt/total equity--
Total debt/total capital1.73
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.